Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Gains from Sales and Divestitures (2016)

Historic Gains from Sales and Divestitures for Viridian Therapeutics, Inc.\DE (VRDN) over the last 3 years, with Q4 2016 value amounting to $52668.0.

  • Viridian Therapeutics, Inc.\DE's Gains from Sales and Divestitures fell 8853.07% to $52668.0 in Q4 2016 from the same period last year, while for Dec 2016 it was $52668.0, marking a year-over-year decrease of 8853.07%. This contributed to the annual value of $52668.0 for FY2016, which is 8853.07% down from last year.
  • As of Q4 2016, Viridian Therapeutics, Inc.\DE's Gains from Sales and Divestitures stood at $52668.0, which was down 8853.07% from $154308.0 recorded in Q3 2016.
  • Viridian Therapeutics, Inc.\DE's 5-year Gains from Sales and Divestitures high stood at $459208.0 for Q4 2015, and its period low was $2352.0 during Q1 2016.
  • Over the past 3 years, Viridian Therapeutics, Inc.\DE's median Gains from Sales and Divestitures value was $154308.0 (recorded in 2016), while the average stood at $200390.3.
  • As far as peak fluctuations go, Viridian Therapeutics, Inc.\DE's Gains from Sales and Divestitures soared by 6118.61% in 2015, and later plummeted by 9815.19% in 2016.
  • Viridian Therapeutics, Inc.\DE's Gains from Sales and Divestitures (Quarter) stood at $284893.0 in 2014, then surged by 61.19% to $459208.0 in 2015, then plummeted by 88.53% to $52668.0 in 2016.
  • Its Gains from Sales and Divestitures was $52668.0 in Q4 2016, compared to $154308.0 in Q3 2016 and $128956.0 in Q2 2016.